Product Information
Ralinepag is a prostacyclin analog that is used in the treatment of chronic heart failure. It was approved for use in Japan in 2016 and is currently being tested for efficacy in the US and European Union. Ralinepag has been shown to be effective at reducing hospitalizations, improving quality of life, and reducing symptoms of chronic heart failure with reduced long-term mortality. Ralinepag binds to the prostacyclin receptor and inhibits cell growth by blocking tyrosine kinase activity. It also reduces inflammation by inhibiting leukocyte migration and adhesion, as well as platelet aggregation. This drug has been shown to be effective in patients with cancer, but also has been associated with side effects such as nausea and diarrhea. The terminal half-life of ralinepag is approximately 90 hours, which may make it advantageous over other drugs that have shorter half-lives.
